Deutsche Bank set a €40.00 ($46.51) price objective on Evonik Industries (FRA:EVK) in a research note released on Friday morning, Borsen Zeitung reports. The brokerage currently has a buy rating on the stock.
Several other brokerages have also weighed in on EVK. Kepler Capital Markets set a €25.00 ($29.07) price objective on shares of Evonik Industries and gave the company a sell rating in a report on Tuesday, May 7th. Morgan Stanley set a €34.00 ($39.53) price objective on shares of Evonik Industries and gave the company a buy rating in a report on Monday, July 15th. Credit Suisse Group set a €28.00 ($32.56) price objective on shares of Evonik Industries and gave the company a neutral rating in a report on Friday, April 12th. DZ Bank reiterated a buy rating on shares of Evonik Industries in a report on Friday, June 14th. Finally, Sanford C. Bernstein set a €31.00 ($36.05) price objective on shares of Evonik Industries and gave the company a buy rating in a report on Thursday. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and ten have assigned a buy rating to the company. The stock has an average rating of Hold and a consensus target price of €30.83 ($35.85).
EVK traded down €1.24 ($1.44) during trading on Friday, reaching €23.41 ($27.22). 1,495,950 shares of the stock traded hands. The company has a 50-day simple moving average of €25.48. Evonik Industries has a 12 month low of €26.78 ($31.14) and a 12 month high of €32.97 ($38.34).
Evonik Industries AG engages in the specialty chemicals business worldwide. It operates through Nutrition & Care, Resource Efficiency, Performance Materials, and Services segments. The Nutrition & Care segment offers specialty chemicals, including amphoteric surfactants, ceramides, phytosphingosines, oleochemicals, quaternary derivatives, polyurethane additives, organically modified silicones, superabsorbents, amino acids and amino acid derivatives, synthesis products, pharmaceutical polymers, and DL-methionine for use in consumer goods, and animal nutrition and healthcare products.
Featured Story: Exchange-Traded Funds (ETFs)
Receive News & Ratings for Evonik Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evonik Industries and related companies with MarketBeat.com's FREE daily email newsletter.